University of Glasgow spinout Chemify, which uses a computing process to design new molecules with AI before making them in an automated lab, raised $43M
Clive Cookson / Financial Times :
Context & Ripple Effects
Chemify's $43M round put the University of Glasgow spinout on the map as a 'design-make' company: AI proposes molecules, a robotic lab synthesizes them, closing the loop between computational design and wet-lab validation. The model has since compounded — Chemify later raised a $50M+ Series B to scale AI- and robotics-driven molecule discovery for pharma clients.
The raise also sits inside a broader funding wave for AI-native chemistry: Inceptive's $100M round from Nvidia and a16z for AI-designed mRNA molecules, Cradle's protein-design Series A, and Singapore's ChemLex raising $45M led by Granite Asia to build a competing automated chemistry lab all point to investors treating the design-make stack as a category, not a one-off.
First-order effects
- Chemify gets the capital to industrialize its automated lab, converting academic chemistry at the University of Glasgow into a service business whose customers are pharmaceutical companies buying novel molecules.
Second-order effects
- ChemLex's $45M round for a rival AI-powered, automated chemistry lab shows the model is now contested territory — pharma buyers gain multiple design-make suppliers, pressuring pricing and speed-to-molecule rather than access itself.
Third-order effects
- If design-make platforms keep raising at this cadence, drug discovery's bottleneck shifts from synthesis capacity to which platform's AI design engine produces the most valuable molecules — and pharma increasingly outsources early molecule creation to these labs rather than building equivalent in-house capability.
The trend: Chemistry and drug discovery are consolidating around AI-design-plus-robotic-synthesis platforms, with venture capital racing to fund the closed design-make loop across molecules, mRNA, and proteins.